1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice.
Carbamazepine (CBZ) is used in the treatment of generalized tonic clonic and partial seizures. In seizure disorder the focal point of treatment is brain. At present no commercial parenteral formulation of CBZ is available. We developed o/w nanoemulsions of CBZ stabilized by 1-O-alkylglycerol/lecithin for intravenous administration and evaluated the brain targeting potential of these formulations. The nanoemulsions were characterized for globule size, zeta potential (ZP), CBZ content and in vivo tissue distribution in mice. The in vivo data revealed a significant uptake of CBZ in all tissues. Among the nanoemulsions, 1-O-decylglycerol stabilized system showed significantly higher tissue levels and availability of CBZ. Particularly for this system 2.37 times higher brain availability and a brain/serum concentration ratio of 3.0 at 30 min is an important finding. This indicates the brain targeting potential. A systematic formulation development of CBZ nanoemulsions employing 1-O-alkylglycerols might pave way to achieve selective brain delivery of this important antiepileptic drug.
Madhusudhan
B
B
University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh, 506 009, India.
Rambhau
D
D
Apte
S S
SS
Gopinath
D
D
D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002220:Carbamazepine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004655:Emulsions; D005990:Glycerol / Q000031:analogs & derivatives* / Q000737:chemistry; D007262:Infusions, Intravenous; D008297:Male; D051379:Mice; D036103:Nanotechnology; D014018:Tissue Distribution
D000927:Anticonvulsants; D004655:Emulsions; D002220:Carbamazepine; D005990:Glycerol